Faculty

Back to Index
Mitchell E. Gross, MD, PhD
Associate Professor of Clinical Medicine
Medicine
CSC 240 Health Sciences Campus Los Angeles
+1 310 272 7640

Overview

Dr. Gross is research director of the USC Norris Westside Cancer Center and the Center for Applied Molecular Medicine. His overall research interest focuses on applying modern techniques relating to the study of genes and proteins (genomics and proteomics) on the clinical problems faced in treating patients with prostate cancer. A particular interest relates to the androgen receptor and relating proteins and pathways as key driving forces behind the development and treatment of prostate cancer. As a medical oncologist, his clinical activities are focused on therapeutic clinical trials incorporating both molecularly targeted and conventional therapies to the care of patients with prostate cancer. He serves as primary investigator on many multi-center phase 1 and 2 clinical trials

Dr. Gross has earned degrees from the University of California, San Diego (B.A.), Baylor College of Medicine in Houston (M.D.), and the University of California, Los Angeles (Ph.D. Molecular Biology). He completed a residency in internal medicine and a fellowship in hematology and medical oncology at the UCLA Center for the Health Sciences.

Awards

Donna and Jesse Garber Award

AACR-AFLAC Scholar in Training Award,

Amgen Fellowship Research Award

Rhone Phoulenc Rorer Travel Award

Specialty Training Advanced Research Fellowship

Hewlett Packard Award for Excellence in Internal Medicine

Alpha Omega Alpha

UCSD/Revelle College Academic: Leadership Award, 1990

Phi Beta Kappa

Publications

van den Bos W, Muller BG, de Bruin DM, de Castro Abreu AL, Chaussy C, Coleman JA, Finelli A, Gill IS, Gross ME, Jenniskens SF, Kahmann F, Laguna-Pes MP, Rastinehad AR, Simmons LA, Sulser T, Villers A, Ward JF, de la Rosette JJ. Salvage ablative therapy in prostate cancer: International multidisciplinary consensus on trial design. Urol Oncol. 2015 Nov; 33(11):495. e1-7. View in: PubMed

Ukimura O, Marien A, Palmer S, Villers A, Aron M, de Castro Abreu AL, Leslie S, Shoji S, Matsugasumi T, Gross M, Dasgupta P, Gill IS. Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies. World J Urol. 2015 Nov; 33(11):1669-76. View in: PubMed

Ukimura O, Gross ME, de Castro Abreu AL, Azhar RA, Matsugasumi T, Ushijima S, Kanazawa M, Aron M, Gill IS. A novel technique using three-dimensionally documented biopsy mapping allows precise re-visiting of prostate cancer foci with serial surveillance of cell cycle progression gene panel. Prostate. 2015 Jun; 75(8):863-71. View in: PubMed

Eisenberg SA, Kurita K, Taylor-Ford M, Agus DB, Gross ME, Meyerowitz BE. Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors. Psychooncology. 2015 Feb; 24(2):228-35. View in: PubMed

Patel N, Itakura T, Jeong S, Liao CP, Roy-Burman P, Zandi E, Groshen S, Pinski J, Coetzee GA, Gross ME, Fini ME. Expression and Functional Role of Orphan Receptor GPR158 in Prostate Cancer Growth and Progression. PLoS One. 2015; 10(2):e0117758. View in: PubMed

Gross ME. Blood-based gene expression profiling in castrate-resistant prostate cancer. BMC Med. 2015; 13(1):219. View in: PubMed

Dorff TB, Gross ME. Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer? Am Soc Clin Oncol Educ Book. 2015; 35:e270-3. View in: PubMed

Dreicer R, Maclean D, Suri A, Stadler WM, Shevrin D, Hart L, Macvicar GR, Hamid O, Hainsworth J, Gross ME, Shi Y, Webb IJ, Agus DB. Phase I/II Trial of Orteronel (TAK-700)--an Investigational 17,20-Lyase Inhibitor--in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2014 Mar 1; 20(5):1335-44. View in: PubMed

Dago AE, Stepansky A, Carlsson A, Luttgen M, Kendall J, Baslan T, Kolatkar A, Wigler M, Bethel K, Gross ME, Hicks J, Kuhn P. Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells. PLoS One. 2014; 9(8):e101777. View in: PubMed

Gross ME. Prostate cancer: Age is nothing but a number. Nat Rev Urol. 2013 Dec; 10(12):683-4. View in: PubMed

Taylor-Ford M, Meyerowitz BE, D'Orazio LM, Christie KM, Gross ME, Agus DB. Body image predicts quality of life in men with prostate cancer. Psychooncology. 2013 Apr; 22(4):756-61. View in: PubMed

Kani K, Malihi PD, Jiang Y, Wang H, Wang Y, Ruderman DL, Agus DB, Mallick P, Gross ME. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate. 2013 Feb 15; 73(3):306-15. View in: PubMed

Amato RJ, Wilding G, Bubley G, Loewy J, Haluska F, Gross ME. Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer. Clin Genitourin Cancer. 2012 Dec; 10(4):232-8. View in: PubMed

Bahn D, de Castro Abreu AL, Gill IS, Hung AJ, Silverman P, Gross ME, Lieskovsky G, Ukimura O. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3. 7 years. Eur Urol. 2012 Jul; 62(1):55-63. View in: PubMed

Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Gross ME, Pinski JK, Quinn DI. Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate Cancer. Clin Nucl Med. 2012 Jul; 37(7):637-43. View in: PubMed

Kani K, Faca VM, Hughes LD, Zhang W, Fang Q, Shahbaba B, Luethy R, Erde J, Schmidt J, Pitteri SJ, Zhang Q, Katz JE, Gross ME, Plevritis SK, McIntosh MW, Jain A, Hanash S, Agus DB, Mallick P. Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition. Mol Cancer Ther. 2012 May; 11(5):1071-81. View in: PubMed

Ukimura O, Desai MM, Palmer S, Valencerina S, Gross M, Abreu AL, Aron M, Gill IS. 3-dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion. J Urol. 2012 Mar; 187(3):1080-6. View in: PubMed

Lazar DC, Cho EH, Luttgen MS, Metzner TJ, Uson ML, Torrey M, Gross ME, Kuhn P. Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate-tumor-derived LNCaP cell line. Phys Biol. 2012 Feb; 9(1):016002. View in: PubMed

Gross ME, Leichman L, Lowe ES, Swaisland A, Agus DB. Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Cancer Chemother Pharmacol. 2012 Jan; 69(1):273-80. View in: PubMed

Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, Keller ET, Hussain M. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs. 2011 Dec; 29(6):1432-40. View in: PubMed

Yu EY, Massard C, Gross ME, Carducci MA, Culine S, Hudes G, Posadas EM, Sternberg CN, Wilding G, Trudel GC, Paliwal P, Fizazi K. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology. 2011 May; 77(5):1166-71. View in: PubMed

Quinn D, Gross M. Show us a sign: the search for "game changing" prostate cancer biomarkers. Lancet Oncol. 2011 Mar; 12(3):204-6. View in: PubMed

Dorff TB, Gross ME. The epothilones: new therapeutic agents for castration-resistant prostate cancer. Oncologist. 2011; 16(10):1349-58. View in: PubMed

Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem. 2010 Sep; 56(9):1492-5. View in: PubMed

Mink SR, Hodge A, Agus DB, Jain A, Gross ME. Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling. Prostate. 2010 Aug; 70(11):1201-10. View in: PubMed

Christie KM, Meyerowitz BE, Giedzinska-Simons A, Gross M, Agus DB. Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and coping. Psychooncology. 2009 May; 18(5):508-14. View in: PubMed

Müller CI, Miller CW, Hofmann WK, Gross ME, Walsh CS, Kawamata N, Luong QT, Koeffler HP. Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leuk Res. 2007 Jan; 31(1):27-32. View in: PubMed

Shazer RL, Luthringer D, Agus DB, Gross ME. Ductal adenocarcinoma of the prostate. Clin Adv Hematol Oncol. 2004 Jun; 2(6):393-5; discussion 396. View in: PubMed

Gross ME, Shazer RL, Agus DB. Targeting the HER-kinase axis in cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 3):9-20. View in: PubMed

Gross ME, Jo S, Agus DB. Update on HER-kinase-directed therapy in prostate cancer. Clin Adv Hematol Oncol. 2004 Jan; 2(1):53-6, 64. View in: PubMed

Powered bySC CTSI